After Blood Plasma Emergency Use Authorization, Can Takeda Develop A More Potent Alternative?

Hyperimmune Globulin Could Prove Superior

After the FDA's emergency use authorization for convalescent plasma, pushed on by President Trump, an alliance of firms is working with the NIH to conduct a robust study of a potentially more potent alternative.

Covid19_Plasma — Hyperimmune-globulin (H-Ig) is a more advanced version of convalescent plasma, which the alliance hope to demonstrate the benefits of in an NIH-sponsored trial.

A group of companies calling itself the “CoVIg-19 Plasma Alliance”, led by Takeda Pharmaceutical Company Limited. and CSL Behring, is poised to start a randomized trial for hyperimmune globulin – a potentially more potent and convenient alternative to convalescent plasma therapy.

The move is significant as convalescent plasma has just been given an Emergency Use Authorization (EUA) by the US Food and Drug Administration to help treat COVID-19 patients, and proclaimed as a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Genentech, Orionis Stick Together In Second Molecular Glue Deal

21 May 2025

• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

21 May 2025

• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

End Is Nigh For 4SC After EMA’s No For Kinselby

21 May 2025

• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

21 May 2025

• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

PureTech’s IPF Candidate Ready For Phase III After Efficacy Win

21 May 2025

• By Andrew McConaghie

Coming one day after Boehringer’s underwhelming data, PureTech’s tweaked molecule, deupirfenidone, shows promise in slowing idiopathic pulmonary fibrosis.